In the pharmaceutical industry, Sodium Valproate is a broad-spectrum anticonvulsant and mood stabilizer. As a pharmacist and manufacturer, I view this molecule as a “Multimodal GABA Enhancer”—it is technically unique because it employs at least three distinct mechanisms to stabilize overactive neuronal membranes, making it effective where other single-mechanism drugs fail.
At your WHO-GMP facility in Mumbai, Sodium Valproate 200 mg is a core “Neurology & Psychiatry” SKU. For your digital platforms, highlighting its versatility across different seizure types is a major technical differentiator for B2B buyer interest.
Therapeutic Profile: Primary Indications
The 200 mg strength is typically used for initial titration in adults or as a maintenance dose in pediatric patients.
| Indication | Clinical Context | Technical Rationale |
| Epilepsy | Broad Spectrum | First-line for generalized (tonic-clonic, absence, myoclonic) and focal seizures. |
| Bipolar Disorder | Mood Stabilization | Used to treat acute manic episodes and as long-term prophylaxis against mood swings. |
| Migraine Prophylaxis | Neurology Focus | Reduces the frequency and intensity of chronic migraine headaches (200 mg is a common starting dose). |
| Aggression / Impulsivity | Off-Label | Occasionally used in specialized psychiatry to manage behavioral disturbances. |
Mechanism: Triple Action Stabilization
Sodium Valproate works by “calming” the brain through three specific chemical pathways:
GABA Enhancement: It inhibits the enzymes that break down GABA (the brain’s primary inhibitory neurotransmitter), increasing its calming effect.
Sodium Channel Blockade: It limits the high-frequency firing of neurons by prolonging the inactive state of voltage-gated sodium channels.
T-Type Calcium Blockade: Technically, it also modulates calcium currents, which is why it is uniquely effective for Absence Seizures.
The Pharmacist’s “Technical Warning”
-
The “Pregnancy” Contraindication: Critical Safety Note: Sodium Valproate is highly teratogenic. It is strictly contraindicated in women of childbearing age unless no other treatment works, due to high risks of neural tube defects and developmental delays.
-
Hepatotoxicity (Liver Safety): As a pharmacist, I must emphasize that liver failure is a rare but serious risk, especially in the first 6 months of therapy. Baseline and periodic Liver Function Tests (LFTs) are mandatory.
-
Pancreatitis Alert: Patients should be warned to report sudden, severe abdominal pain immediately, as Acute Pancreatitis is a technical risk associated with valproate therapy.
-
Weight Gain & PCOS: Long-term use is associated with significant weight gain and a potential increased risk of Polycystic Ovary Syndrome (PCOS) in young women.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
-
The “Enteric-Coated” USP: On your digital marketplace, highlight your Enteric-Coated (EC) 200 mg tablets. This technical coating prevents the drug from dissolving in the stomach, significantly reducing the common “gastric irritation” side effect.
-
Stability for Export: Sodium Valproate is highly hygroscopic (it absorbs moisture from the air and can liquefy). Utilizing Alu-Alu blister packaging is the absolute requirement for ensuring a 36-month shelf life in Zone IVb tropical regions.
-
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers to support your firm’s registration in international tenders for mental health and neurology programs.